Coverage from the ASCO20 Virtual Scientific Program
Focus on Lung Cancer
New! KRAS Mutations Characterized in Non-Small Cell Lung Cancer
KRAS is the most commonly mutated oncogene in non-small cell lung cancer (NSCLC) and the development of direct KRAS inhibitors has renewed interest in this molecular subtype. However, there are several different KRAS mutations, representing unique biology and different prognostic and therapeutic impact.
Chemo/immunotherapy Combo Promising for Treatment of Mesothelioma
Inoperable malignant pleural mesothelioma is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos. At the annual meeting of the ASCO 2020 Annual Meeting, held virtually May 29-31, a researcher from the Johns Hopkins Kimmel Cancer Center presented findings from a multicenter study that evaluated the efficacy of an immunotherapy/ chemotherapy combination for the disease (Abstract 9003).
Addition of Durvalumab to Platinum + Etoposide in Extensive-Stage SCLC
Updated results from the CASPIAN study support the addition of durvalumab to platinum and etoposide as a new standard of care in extensive-stage small cell lung cancer (ES-SCLC). Results were presented at ASCO 2020 Annual Meeting (Abstract 9002).
Immunotherapy Combo Plus Chemo Improves Survival in First-Line NSCLC
Findings from the phase III CheckMate-9LA trial demonstrated that nivolumab plus ipilimumab, given concomitantly with 2 cycles of chemotherapy, had a statistically significant and clinically meaningful survival benefit as a first-line treatment of metastatic non-small cell lung cancer (NSCLC).
Survivors of Childhood Malignancies Face Risk of Developing Lung Cancer
A recent study showed that childhood cancer survivors are at an increased risk for lung cancer. Risk factors include increased age at diagnosis, high doses of chest radiotherapy, and primary diagnoses of Hodgkin lymphoma, neuroblastoma, and bone cancer, according to data presented at the ASCO 2020 Annual Meeting (Abstract 10551).
Pembrolizumab + Chemo Continues to Improve Efficacy in Metastatic Nonsquamous NSCLC
With longer follow-up, pembrolizumab plus chemotherapy continued to improve efficacy outcomes in previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC) over placebo and chemotherapy, with a manageable toxicity profile, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 9582).